insights_auto
Outlook: 11.8% bullish·35.3% bearish
Go to analysischevron_right
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$331.90
arrow_upward
+0.65%(+2.15) 1D
Sep 30, 11:31:25 AM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMYB34...
Mkt. cap
120.77B
Avg. vol.
3.00
Volume
0.00
52-wk high
R$347.15
52-wk low
R$221.72
Shares outstanding
2.04B
No. of employees
32K
Mkt. cap
120.77B
Avg. vol.
3.00
Volume
0.00
52-wk high
R$347.15
52-wk low
R$221.72
Shares outstanding
2.04B
No. of employees
32K
News stories
From web sources and news partners
AD HOC NEWS
·
8 hours ago
Bristol Myers Squibb stock loses 0.56 percent after-hours to EUR 53.22
MarketBeat
·
9 hours ago
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn
AD HOC NEWS
·
14 hours ago
Leerink downgrades Bristol Myers Squibb stock to Market Perform
The Globe and Mail
·
17 hours ago
Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com
Last report
Jul 30, 2026
Fiscal period
Q2 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$2.04 / $1.60
+27.74%beat
arrow_upward
Revenue / Est. (USD)
12.97B / 11.74B
+10.53%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 12.22B | 12.50B | 11.49B | 12.97B |
Cost of goods sold | 3.31B | 3.51B | 3.41B | 3.71B |
Cost of revenue | 3.31B | 3.51B | 3.41B | 3.71B |
Research and development expenses | 2.43B | 2.56B | 2.24B | 2.54B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.79B | 2.09B | 1.61B | 1.82B |
Operating expense | 5.05B | 5.47B | 4.28B | 4.80B |
Total operating expenses | 8.36B | 8.98B | 7.69B | 8.51B |
Operating income | 3.86B | 3.52B | 3.80B | 4.46B |
Other non operating income | 529.00M | 544.00M | 125.00M | 106.00M |
EBT including unusual items | 3.11B | 1.47B | 3.24B | 4.09B |
EBT excluding unusual items | 4.07B | 3.86B | 3.65B | 4.35B |
Income tax expense | 919.00M | 384.00M | 561.00M | 770.00M |
Effective tax rate | 29.51% | 26.12% | 17.32% | 18.84% |
Other operating expenses | - | - | - | - |
Net income | 2.20B | 1.09B | 2.68B | 3.32B |
Net profit margin | 18.01% | 8.69% | 23.30% | 25.57% |
Earnings per share | 1.63 | 1.26 | 1.58 | 2.04 |
Interest and investment income | 161.00M | 148.00M | 104.00M | 101.00M |
Interest expense | -482.00M | -432.00M | -406.00M | -403.00M |
Net interest expenses | -321.00M | -284.00M | -302.00M | -302.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 4.91B | 4.54B | 4.41B | 5.08B |
Gain or loss from assets sale | -9.00M | - | -34.00M | -142.00M |